Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.42 |
| ▸ | MMP9 | P14780 | 6/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108503 | 1.00 | PGR (0.46) | PGRMMP2MMP9MMP3MMP13 | |
| SCHEMBL1108549 | 0.91 | PGR (0.44) | PGRMMP2MMP9MMP3MMP13 | |
| SCHEMBL1108464 | 0.91 | LMNA (0.42) | MMP2MMP9LMNAHTTSMN1; SMN2 | |
| SCHEMBL1099181 | 0.91 | LMNA (0.42) | MMP2MMP9LMNAHTTSMN1; SMN2 | |
| SCHEMBL1100371 | 0.91 | PGR (0.44) | PGRMMP2MMP9MMP3MMP13 | |
| SCHEMBL1108535 | 0.89 | FFAR1 (0.45) | MMP2MMP9MMP13LMNAHTT | |
| SCHEMBL1100932 | 0.89 | FFAR1 (0.45) | MMP2MMP9MMP13LMNAHTT | |
| SCHEMBL1108565 | 0.88 | LMNA (0.40) | PGRMMP2MMP9MMP13LMNA | |
| SCHEMBL1101042 | 0.88 | LMNA (0.40) | PGRMMP2MMP9MMP13LMNA | |
| SCHEMBL1108568 | 0.87 | LIPE (0.40) | PGRMMP2MMP9MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1962641-B | Metalloproteinase inhibitors | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| CN-1962641-A | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-05-16 | — | — | CN | disclosed |
| CN-1269804-C | Metalloprotease inhibitors | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| CN-1509275-A | Metalloproteinase inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| CN-1509276-A | Metalloprotease inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | PGR 3527/4885MMP2 9/4885MMP9 1/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | PGR 3527/4885MMP2 9/4885MMP9 1/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | PGR 2805/4885MMP2 8/4885MMP9 1/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | PGR 860/4885MMP2 11/4885MMP9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.